RBC Bioscience

RBC Bioscience Pre-Tax Margin

The Pre-Tax Profit Margin of RBC Bioscience (6848.TWO) as of Nov 6, 2026 is 13.14 %. In the previous year, Pre-Tax Profit Margin was 4.56 % — a change of 187.77% (higher).

Pre-Tax Margin

13.14 %

YoY

187.77%

Last updated:

Pre-Tax Profit Margin of RBC Bioscience is 2024 13.14 % . Pre-Tax Profit Margin of RBC Bioscience was 2023 4.56 % . It decreases by 187.77% higher compared to the previous year.

The RBC Bioscience Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
13.56 TWD
Jan 1, 2019
11.15 TWD
Jan 1, 2020
30.83 TWD
Jan 1, 2021
14.31 TWD
Jan 1, 2022
2.83 TWD
Jan 1, 2023
4.56 TWD
Jan 1, 2024
13.14 TWD
The RBC Bioscience Pre-Tax Margin history
YEARPre-Tax MarginYoY
13.14 %+187.77%
4.56 %+61.47%
2.83 %-80.25%
14.31 %-53.59%
30.83 %+176.52%
11.15 %-17.80%
13.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Pre-Tax Profit Margin of RBC Bioscience is 13.14 % in 2024.

Pre-Tax Profit Margin of RBC Bioscience changed from 4.56 % to 13.14 %, representing a 187.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RBC Bioscience

All Key Metrics — RBC Bioscience